Our mission is to transform cancer diagnostics and treatment prediction through advanced phenotype mapping — reshaping the future of precision medicine.
Myriad Genetics
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
PATHOMIQ Announces Data Presentation on an AI-powered tool that Predicts Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy at the San Antonio Breast Cancer Symposium (SABCS) 2022